ArticleThe Journal of thoracic and cardiovascular surgery2025
Surgical and long-term outcomes of combined organ resection for esophageal cancer invading adjacent organs: Experience of 90 consecutive cases.
Article in The Journal of thoracic and cardiovascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.BMC medicine · 2025Trial
- Treatment-dependent and independent prognostic value of inflammation-based nutritional indices in immune checkpoint inhibitor-based therapy for esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Initial clinical outcomes of uniportal robotic-assisted minimally invasive esophagectomy.Surgical endoscopy · 2026Article
- Surgical technique for partial-layer tracheal resection for esophageal cancer with tracheal invasion.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Refining the role of extended resection in multidisciplinary treatment for cT4b esophageal cancer.Journal of thoracic disease · 2026Article
- Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study.Cancer immunology, immunotherapy : CII · 2026Article
- Combined organ resection for esophageal cancer invading adjacent organs is becoming a safe and curative procedure.Journal of thoracic disease · 2026Article
- Reassessing the role of combined organ resection in cT4b esophageal cancer: feasibility, outcomes, and future directions.Journal of thoracic disease · 2026Article
- Can combined organ resection cure T4 esophageal cancer? Insights from a multi-institutional study of incomplete resection cases.Esophagus : official journal of the Japan Esophageal Society · 2026Observational
- Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review.Annals of gastroenterological surgery · 2026Review
- Prognostic impact of different lymph node staging systems in patients with esophageal squamous cell carcinoma.Surgical endoscopy · 2026Article
- Conversion surgery following immunochemotherapy for initially unresectable/recurrent esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- DeepSeek's impact on thoracic surgeons' work patterns-past, present and future.Journal of thoracic disease · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the feasibility of and long-term survival with combined organ resection for esophageal cancer (EC). The optimal treatment strategy for EC that is invading adjacent organs is not established.
methodsNinety patients with EC invading adjacent organs who underwent combined organ resection after induction treatments during the time period 2003-2023 in our institute were eligible for the study. Short- and long-term outcomes were assessed, and survival analysis was performed to identify prognostic parameters in this cohort.
resultsMost patients had primary tumors (78.9% vs 21.1% with recurrent disease). The resected organs were the trachea/bronchus in 75.6%, large vessels in 24.4%, and both in 5.6%. All but 1 patient underwent chemotherapy or chemoradiotherapy as prior induction treatment, and had R0 resection. The overall complication rate (Clavien-Dindo grade II or greater) was 54.4%, and in-hospital mortality was 2.2% (30- and 90-day mortality: 0% and 2.2%, respectively). Of the deaths, 47 (87.0%) were attributed to EC and 7 (13.0%) to other causes. Median disease-free survival was 6.5 months, and overall survival (OS) was 18.9 months. The 2-year OS values were 47.2% with trachea/bronchus resection, 38.4% with large-vessel involvement, and 37.5% if both were involved. Univariate analysis of OS demonstrated significant associations of operation time (hazard ratio [HR], 2.11; P = .0080), blood loss (HR, 2.85; P = .0003), all-layer tracheal resection (HR, 3.51; P = .0045), ypT (HR, 2.04; P = .022), and pathologic response (HR, 2.77; P = .0089).
conclusionsIf patient selection is highly selected, combined organ resection may be a feasible and promising option as a part of the multidisciplinary treatment for EC invading an adjacent organ.
Indexed as
Identifiers
39864736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.